Related Experiment Video
Updated: Aug 9, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary
Hye-Jeong Choi1, Yonghyuk Lee1, Susin Park2
1College of Pharmacy, Pusan National University, Busandaehakro 63 Bungil 2, Geumjeong-Gu, Busan, 46241, Republic of Korea.
Insights
Triple antithrombotic therapy (TAT) use increased significantly for atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) from 2011 to 2020. However, many patients still did not receive optimal antithrombotic treatment.
Area of Science:
- Cardiology
- Pharmacology
- Health Services Research
Background:
- Triple antithrombotic therapy (TAT), combining oral anticoagulants and dual antiplatelet therapy (DAPT), is crucial for preventing ischemic events in atrial fibrillation (AF) patients post-percutaneous coronary intervention (PCI).
- Concerns regarding bleeding risk limit the widespread adoption of TAT.
- This study investigates TAT utilization and its determinants in the era of non-vitamin K antagonist oral anticoagulants (NOACs) using real-world data.
Purpose of the Study:
- To analyze the trends in utilization of triple antithrombotic therapy (TAT) among patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI).
- To identify demographic and clinical factors influencing the adoption of TAT in the NOACs era.
- To assess the adequacy of antithrombotic therapy in this high-risk patient population.
Main Methods:
- Analysis of the National Inpatient Sample data from 2011-2020.
- Inclusion of patients with AF who underwent PCI with stent implantation and had increased stroke risk.
- Investigation of demographic and clinical factors using chi-squared test, Student t-test, and multiple logistic regression.
Main Results:
- TAT utilization increased from 30.3% in 2011 to 65.4% in 2020 (p < 0.001).
- Positive factors for TAT use included congestive heart failure, prior stroke/TIA/thromboembolism, valvular heart disease, and the study year.
- Negative factors included specific insurance types, medical institution type, and comorbidities like renal disease, liver disease, and prior hemorrhage history.
Conclusions:
- TAT use in high-stroke risk AF patients undergoing PCI showed a steady increase between 2011 and 2020.
- Despite the increase, 29.4% of patients still received only DAPT in 2020, indicating suboptimal antithrombotic management.
- Further research and clinical practice adjustments are needed to ensure optimal antithrombotic therapy for AF patients post-PCI.
Background:
Triple antithrombotic therapy (TAT), a combination of an oral anticoagulant and dual antiplatelet therapy (DAPT), is a key treatment for prevention of ischemic events in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, TAT is not extensively used because of the risk of bleeding. This study aimed to determine the utilization and influencing factors of TAT using real-world data in the non-vitamin K antagonist oral anticoagulants (NOACs) era.
Methods:
We analyzed National Inpatient Sample data compiled by the Health Insurance Review & Assessment Service (HIRA-NIS) from 2011 to 2020. Patients with AF who underwent PCI with stent implantation and with an increased stroke risk were selected as candidates for TAT therapy. Demographic and clinical factors associated with TAT use were investigated using the chi-squared test and the Student t-test, and influencing factors were identified using multiple logistic regression.
Results:
The TAT utilization rate steadily increased from 30.3% in 2011 to 65.4% in 2020 (Cochran-Armitage trend test: p < 0.001) with an average of 45.9%. Positive influencing factors for TAT use were identified as congestive heart failure, history of previous stroke/transient ischemic attack/thromboembolism, valvular heart disease, and year. Negative influencing factors included insurance type (medical aid or Patriots & Veterans Insurance), type of medical institution (general hospitals or primary medical institutions), and comorbidities such as renal disease, liver disease, and history of the previous hemorrhage.
Conclusions:
The utilization of TAT following PCI among high-stroke risk AF patients steadily increased from 2011 to 2020, reaching 65.4% by the end of the study period. However, in 2020, a significant proportion of 29.4% of patients still received DAPT, indicating that many AF patients undergoing PCI did not receive adequate antithrombotic therapy.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

